Histogen Inc. (HSTO): Price and Financial Metrics
HSTO Price/Volume Stats
| Current price | $0.35 | 52-week high | $1.05 |
| Prev. close | $0.35 | 52-week low | $0.05 |
| Day low | $0.35 | Volume | 6,900 |
| Day high | $0.40 | Avg. volume | 21,586 |
| 50-day MA | $0.38 | Dividend yield | N/A |
| 200-day MA | $0.49 | Market Cap | 1.50M |
HSTO Stock Price Chart Interactive Chart >
Histogen Inc. (HSTO) Company Bio
Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.
Latest HSTO News From Around the Web
Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.
Histogen to Explore Strategic AlternativesSAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic with traders on Thursday as we go over the shares seeing the biggest movements this morning. |
Histogen Reports First Quarter 2023 Results and Provides Business UpdateReceived FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia |
Histogen Announces Online Publication in the Journal of Investigative DermatologyEmricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! |
HSTO Price Returns
| 1-mo | -12.50% |
| 3-mo | -5.41% |
| 6-mo | 9.17% |
| 1-year | -61.65% |
| 3-year | -98.36% |
| 5-year | -99.77% |
| YTD | 13.75% |
| 2023 | -62.93% |
| 2022 | -87.53% |
| 2021 | -56.11% |
| 2020 | -81.05% |
| 2019 | -76.88% |
Loading social stream, please wait...